Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 11;370(6522):1339-1343.
doi: 10.1126/science.abe1107. Epub 2020 Nov 6.

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Kevin W Ng  1 , Nikhil Faulkner  1 , Georgina H Cornish  1 , Annachiara Rosa  2 , Ruth Harvey  3 , Saira Hussain  3 , Rachel Ulferts  4 , Christopher Earl  5 , Antoni G Wrobel  6 , Donald J Benton  6 , Chloe Roustan  7 , William Bolland  1 , Rachael Thompson  1 , Ana Agua-Doce  8 , Philip Hobson  8 , Judith Heaney  9 , Hannah Rickman  9 , Stavroula Paraskevopoulou  9 , Catherine F Houlihan  9   10 , Kirsty Thomson  9 , Emilie Sanchez  9 , Gee Yen Shin  9 , Moira J Spyer  9   11 , Dhira Joshi  12 , Nicola O'Reilly  12 , Philip A Walker  7 , Svend Kjaer  7 , Andrew Riddell  8 , Catherine Moore  13 , Bethany R Jebson  14   15 , Meredyth Wilkinson  14   15 , Lucy R Marshall  14   15 , Elizabeth C Rosser  14   16 , Anna Radziszewska  14   16 , Hannah Peckham  14   16 , Coziana Ciurtin  14   16 , Lucy R Wedderburn  14   15 , Rupert Beale  4 , Charles Swanton  17 , Sonia Gandhi  18 , Brigitta Stockinger  19 , John McCauley  3 , Steve J Gamblin  6 , Laura E McCoy  20 , Peter Cherepanov  21 , Eleni Nastouli  22   11 , George Kassiotis  23   24
Affiliations

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Kevin W Ng et al. Science. .

Abstract

Zoonotic introduction of novel coronaviruses may encounter preexisting immunity in humans. Using diverse assays for antibodies recognizing SARS-CoV-2 proteins, we detected preexisting humoral immunity. SARS-CoV-2 spike glycoprotein (S)-reactive antibodies were detectable using a flow cytometry-based method in SARS-CoV-2-uninfected individuals and were particularly prevalent in children and adolescents. They were predominantly of the immunoglobulin G (IgG) class and targeted the S2 subunit. By contrast, SARS-CoV-2 infection induced higher titers of SARS-CoV-2 S-reactive IgG antibodies targeting both the S1 and S2 subunits, and concomitant IgM and IgA antibodies, lasting throughout the observation period. SARS-CoV-2-uninfected donor sera exhibited specific neutralizing activity against SARS-CoV-2 and SARS-CoV-2 S pseudotypes. Distinguishing preexisting and de novo immunity will be critical for our understanding of susceptibility to and the natural course of SARS-CoV-2 infection.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1. Flow cytometric detection and specificity of antibodies reactive with SARS-CoV-2 S.
(A) Detection of IgG, IgA, and IgM in five individuals from each indicated group. IgM levels are indicated by a heatmap. (B to D) Inhibition of SARS-CoV-2 S binding of sera from SARS-CoV-2–infected (SARS-CoV-2+, n = 10) or SARS-CoV-2–uninfected (SARS-CoV-2− HCoV+, n = 6) patients by soluble S1 or S2. (B) Flow cytometry profile of one representative patient per group. (C) Mean frequency of positive cells. *P = 0.015; **P = 0.006, one-way analysis of variance (ANOVA) on ranks. (D) Mean staining intensity [mean fluorescence intensity (MFI) of sample as a percentage of negative control MFI]. In (C) and (D), dots represent individual samples from one of three similar experiments.
Fig. 2
Fig. 2. Prevalence of SARS-CoV-2 S–cross-reactive antibodies detected by different methods.
(A) Flow cytometry and ELISA results for each sample in cohorts A and C to E listed in table S1. (B) Flow cytometry and ELISA results for serum samples from SARS-CoV-2–uninfected pregnant women. (C to E) SARS-CoV-2 S–cross-reactive antibodies in healthy children and adolescents. (C) Representative flow cytometry profiles of seronegative donors (Negative) or COVID-19 patients (Positive) and of SARS-CoV-2–uninfected adolescents with SARS-CoV-2 cross-reactive antibodies. (D) Frequency of cells stained with all three antibody classes (IgG+IgM+IgA+) or only with IgG (IgG+) ranked by their IgG+IgM+IgA+ frequency. The dashed line denotes the assay sensitivity cutoff. (E) Flow cytometry and ELISA results for each sample. (F) Prevalence of SARS-CoV-2 S–cross-reactive antibodies in the indicated age groups (line) and frequency of cells that stained only with IgG (dots) in all samples for which the date of birth was known. The heatmaps in (A), (B), and (E) represent the quartile values above each assay’s technical cutoff.
Fig. 3
Fig. 3. Neutralization of SARS-CoV-2 S pseudotypes and authentic SARS-CoV-2 by SARS-CoV-2–infected and –uninfected patient sera.
(A) Inhibition of transduction efficiency of SARS-CoV-2 S or VSVg pseudotypes by adult COVID-19 patients who seroconverted (SARS-CoV-2+ Adults Ab+) or not (SARS-CoV-2+ Adults Ab−) and SARS-CoV-2–uninfected adult donors (SARS-CoV-2− Adults Ab+) or children and adolescent donors (SARS-CoV-2− Children/Adolescents Ab+) with SARS-CoV-2 S–binding antibodies. Each line is an individual serum sample. (B) Authentic SARS-CoV-2 neutralization titers of sera from the same donors as in (A), as well as SARS-CoV-2–uninfected donors without SARS-CoV-2 S–binding antibodies (Ab−). Dots represent individual samples. *P = 0.037; **P = 0.014; ns, not significant by one-way ANOVA on ranks.
Fig. 4
Fig. 4. Mapping of cross-reactive epitopes in SARS-CoV-2 S.
(A) Signal intensity for each overlapping peptide along the length of SARS-CoV-2 S covered in the peptide arrays using pooled sera with (Ab+) or without (Ab−) flow cytometry–detectable SARS-CoV-2 S–reactive antibodies. Differentially recognized peaks are boxed. (B) Alignment of the amino acid sequences of SARS-CoV-2 and HCoV S glycoproteins. Boxes indicate predicted core epitopes. (C) Mapping of predicted epitopes targeted on the trimeric SARS-CoV-2 spike. The S1 (blue) and S2 (pink) subunits of one monomer are colored. Epitopes are shown for one monomer; the circled dashed line represent the membrane proximal region not present in the structure. (D) Left: Reactivity with the S glycoproteins of each HCoV of the indicated sera with (Ab+) or without (Ab−) flow cytometry–detectable SARS-CoV-2 S–reactive antibodies as determined by flow cytometry. Each column is an individual sample. Rows depict the staining for each antibody class. Right: Correlation coefficients between percentages of IgG staining for SARS-CoV-2 S and IgG, IgM, and IgA staining for each HCoV S glycoprotein.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aldridge R. W., Lewer D., Beale S., Johnson A. M., Zambon M., Hayward A. C., Fragaszy E. B., Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): Results from the Flu Watch cohort study. Wellcome Open Res. 5, 52 (2020). 10.12688/wellcomeopenres.15812.1 - DOI - PMC - PubMed
    1. Callow K. A., Parry H. F., Sergeant M., Tyrrell D. A., The time course of the immune response to experimental coronavirus infection of man. Epidemiol. Infect. 105, 435–446 (1990). 10.1017/S0950268800048019 - DOI - PMC - PubMed
    1. Severance E. G., Bossis I., Dickerson F. B., Stallings C. R., Origoni A. E., Sullens A., Yolken R. H., Viscidi R. P., Development of a nucleocapsid-based human coronavirus immunoassay and estimates of individuals exposed to coronavirus in a U.S. metropolitan population. Clin. Vaccine Immunol. 15, 1805–1810 (2008). 10.1128/CVI.00124-08 - DOI - PMC - PubMed
    1. Dijkman R., Jebbink M. F., El Idrissi N. B., Pyrc K., Müller M. A., Kuijpers T. W., Zaaijer H. L., van der Hoek L., Human coronavirus NL63 and 229E seroconversion in children. J. Clin. Microbiol. 46, 2368–2373 (2008). 10.1128/JCM.00533-08 - DOI - PMC - PubMed
    1. Huang A. T., Garcia-Carreras B., Hitchings M. D. T., Yang B., Katzelnick L. C., Rattigan S. M., Borgert B. A., Moreno C. A., Solomon B. D., Trimmer-Smith L., Etienne V., Rodriguez-Barraquer I., Lessler J., Salje H., Burke D. S., Wesolowski A., Cummings D. A. T., A systematic review of antibody mediated immunity to coronaviruses: Kinetics, correlates of protection, and association with severity. Nat. Commun. 11, 4704 (2020). 10.1038/s41467-020-18450-4 - DOI - PMC - PubMed

Publication types

MeSH terms